Beijing, CARTITUDE-4, CARVYKTI, China, ciltacabtagene autoleucel, Clinical trials, Legend biotech, refractory multiple myeloma, Shanghai
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI®(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
JANUARY 27, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that ..
Beijing, Biotechnology, Cell therapy, Cellular therapy, China, Cilta-Cel, ciltacabtagene autoleucel, Legend biotech
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
SOMERSET, N.J.—JANUARY 2, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, ann..